Eric Conley, OD
Optometrist · Wantagh, NYNPI 1639202211
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $73,255 of the $115,871 with a category attached, or 63.2%. Glaukos Corporation accounts for 97.8% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2022 at $66,187 and has fallen 98.9% since, to $738 in 2025. Among optometrist clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 141 payments — averaging $821.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$113K
- Tarsus Pharmaceuticals, Inc.$404
- Aerie Pharmaceuticals, Inc.$384
- Eyevance Pharmaceuticals LLC$329
- Bausch & Lomb, A Division Of Bausch Health US, LLC$236
- Oyster Point Pharma, Inc.$206
- plus $1K from 10 others
What the payments were for
- Consulting fees$73,25563%
- Travel & lodging$36,10931%
- Food & beverage$6,4146%
- Education$940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 65 | $113,295 |
| Tarsus Pharmaceuticals, Inc. | 15 | $404 |
| Aerie Pharmaceuticals, Inc. | 9 | $384 |
| Eyevance Pharmaceuticals LLC | 4 | $329 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $236 |
| Oyster Point Pharma, Inc. | 9 | $206 |
| Bausch & Lomb Americas Inc. | 7 | $202 |
| Sun Pharmaceutical Industries Inc. | 4 | $183 |
| AbbVie(2 entities) | 4 | $170 |
| Harrow Eye, LLC | 7 | $148 |
| Alcon | 7 | $147 |
| Novartis | 2 | $43 |
| Ivantis, Inc | 1 | $43 |
| Quidel Corporation | 1 | $39 |
| Shire North American Group Inc | 1 | $22 |
| Johnson & Johnson Vision Care, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ILINK$33,433
- KXL System$32,878
- CE-marked KXLA system$5,491
- iStent inject W$3,275
- Photrexa$951
- XDEMVY$241
- Zerviate$239
- LOTEMAX SM$210
- MIEBO$125
- XIIDRA$125
- Rhopressa$124
- Rocklatan$124
- CEQUA$122
- LUMIGAN$117
How this compares
$115,871 in reported general payments places this provider in the 95th percentile of 2,743 optometrist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MieboPerfluorohexyloctane/Pf | 51 | $43,918 |
| RestasisCyclosporine | 20 | $24,646 |
| Loteprednol Etabonate | 87 | $10,866 |
| RocklatanNetarsudil Mesylat/Latanoprost | 13 | $8,185 |
| VyzultaLatanoprostene Bunod | 15 | $5,258 |
| Travoprost | 29 | $2,859 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 193 | $2,148 |
| Latanoprost | 223 | $1,075 |
| Dexamethasone Sodium Phosphate | 25 | $881 |
| Prednisolone Acetate | 28 | $833 |
| Brimonidine Tartrate | 12 | $466 |
| Dorzolamide Hcl | 27 | $406 |
| Timolol Maleate | 27 | $404 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 21 | $346 |
| Doxycycline Hyclate | 24 | $269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo, Vyzulta | $202 | $49,17666 claims |
| AbbVieRestasis | $170 | $24,64620 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $236 | $10,86687 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $384 | $8,18513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,743 optometrist providers in New York.
Other optometrist in Wantagh
- Roy KlineLake Katrine$822K
- Susan ResnickNew York$463K
- Murray FingeretHewlett$374K
- Albert MorierSlingerlands$347K
- Denise WhittamNew York$343K
- Justin BazanBrooklyn$303K
- Jennifer TsaiNew York$275K
- Alexander KabiriQueens Village$268K
- Sophia VisanjiNew York$233K
- Jason ComptonNew York$181K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.